Richard Champlin, MD
Hematology & Oncology · Houston, TXNPI 1366541054
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,822 of the $40,553 with a category attached, or 80.9%. 10 manufacturers reported payments, led by Omeros Corporation at 55.3% of the total. Reporting peaked in 2021 at $17,355 and has fallen 91.3% since, to $1,513 in 2025.
Across 32 payments — averaging $1267.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Omeros Corporation$22K
- Janssen Research & Development, LLC$13K
- Genetix Biotherapeutics Inc$3K
- Kadmon Pharmaceuticals LLC$2K
- Terumo BCT, Inc.$500
- Vertex$217
- plus $541 from 4 others
Across 10 payments — averaging $50,936 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$164K
- Omeros Corporation$164K
- Sanofi US Services Inc.$134K
- Sanofi$48K
What the payments were for
- Consulting fees$32,82281%
- Speaking & faculty fees$4,65011%
- Travel & lodging$2,3316%
- Food & beverage$7502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Omeros Corporation | 19 | $22,440 |
| Janssen Research & Development, LLC | 2 | $12,500 |
| Genetix Biotherapeutics Inc | 4 | $2,750 |
| Kadmon Pharmaceuticals LLC | 1 | $1,605 |
| Terumo BCT, Inc. | 1 | $500 |
| Vertex | 1 | $217 |
| National Marrow Donor Program | 1 | $215 |
| AstraZeneca | 1 | $150 |
| Jazz Pharmaceuticals Inc. | 1 | $149 |
| Seagen Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- narsoplimab$12,236
- LYFGENIA$2,063
- SKYSONA$1,238
- Zynteglo$550
- Quantum Cell Expansion System$500
- SOLIRIS$150
- VYXEOS$149
How this compares
$40,553 in reported general payments places this provider in the 85th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $26 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.